BioAtla, Inc. (BCAB)
OTC: BCAB · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2020
Who owns BioAtla, Inc.
As filed with the SECHolders of 5% or more
3
Anders Hove holds 8.3% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13G/A filed May 20, 2025 says.
Directors and officers
4
report now, of 14 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Anders Hove
SCHEDULE 13G/A · filed May 20, 2025 · Common Stock, $0.0001 par value per share
Highbridge Capital Management, LLC
SCHEDULE 13G/A · filed Apr 25, 2025 · Common Stock, par value $0.0001 per share · 9.9% in Feb 10, 2025
Jay M. Short
SCHEDULE 13G/A · filed Feb 7, 2025 · Common Stock, par value $0.0001
OPOKA INVESTMENT FUND Co
SCHEDULE 13G · filed Oct 15, 2025 · Common Stocks, par value $0,0001 per share · reported falling below 5%, from 6.1% in Mar 18, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Jan 24, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
What BCAB reports owning in othersstakes of 5% or more, and other ties
BioAtla, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2023 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.